treatment for fibrocystic breast changes

When lesions of uncertain malignant potential are found (B3 in the biopsy classification), complete excision is indicated. Where there is doubt, histological confirmation should be sought by means of percutaneous biopsy.Ĭonclusion: Benign breast changes can be definitively distinguished from malignant lesions through the selective use of available diagnostic investigations and interdisciplinary collaboration. Complex cysts, for example, carry a risk of malignancy of 23% to 31%, papillary lesions 16%, and radial scars 7%. However, it is important in the differential diagnosis to distinguish between such benign changes and breast cancer or changes that carry a risk of malignancy. With most benign breast changes the risk of dedifferentiation is very low. Fibroadenomas occur in 25% of women they are the most common benign tumors of the breast and do not require treatment. Results: Mastalgia and fibrocystic changes are common (around 50% of all women over the age of 30). Methods: Selective literature search of PubMed from 1985 to May 2019, including current national (AWMF, Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften ) and international guidelines. However, there is a lack of up-to-date, evidence-based treatment recommendations for the various benign differential diagnoses. Background: Most clinical breast changes in women are benign in only 3% to 6% of cases are they due to breast cancer.

Treatment for fibrocystic breast changes